Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.58 |
| ▸ | PLA2G4B | P0C869 | 9/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2430018 | 0.92 | CES2 (0.68) | CES2PLA2G4BTSHRPLA2G4A | |
| SCHEMBL13832508 | 0.91 | CES2 (0.50) | CES2PLA2G4BTSHRALDH1A1ATM | |
| SCHEMBL6702677 | 0.90 | CES2 (0.54) | CES2PLA2G4BTSHRALDH1A1ATM | |
| SCHEMBL2865178 | 0.90 | CES2 (0.72) | CES2PLA2G4BTSHRPLA2G4A | |
| SCHEMBL28145928 | 0.88 | CES2 (0.52) | CES2PLA2G4BTSHRALDH1A1ATM | |
| SCHEMBL12814326 | 0.88 | CES2 (0.52) | CES2PLA2G4BTSHRALDH1A1ATM | |
| SCHEMBL12814324 | 0.88 | CES2 (0.52) | CES2PLA2G4BTSHRALDH1A1ATM | |
| SCHEMBL20317552 | 0.86 | CES2 (0.50) | CES2PLA2G4BTSHRALDH1A1ATM | |
| SCHEMBL14614230 | 0.86 | CES2 (0.55) | CES2PLA2G4BTSHRALDH1A1 | |
| SCHEMBL15870674 | 0.86 | CES2 (0.50) | CES2PLA2G4BTSHRALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277279-A1 | Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions | GLAXO GROUP LIMITED | 2012-11-01 | — | — | US | disclosed |
| US-8247377-B2 | Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions | GLAXO GROUP LIMITED (GB) | 2012-08-21 | — | — | US | disclosed |
| US-20100234441-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| EP-1120397-A2 | Process for preparing triazole derivative | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2001-08-01 | — | — | EP | disclosed |
| US-6046354-A | CHEMICAL INTERMEDIATES, E.G. 2-ARYL-1,3-DIACYLOXY-2-PROPANOL, FOR DRUGS AND FUNGICIDES,E.G. (R)-2-(2,4-DIFLUOROPHENYL)-3-(1H-1,2,4-TRIAZOLE-1-YL)-PROPANE-1,2-DIOL, | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2000-04-04 | — | — | US | disclosed |
| US-5840553-A | OPTICALLY ACTIVE 2-ARYL-3-ACYLOXY-1,2,-PROPANE DIOL USING A MICROORGANISM OR ENZYME DERIVED FROM PORCINE PANCREAS; VIA STEREOSPECIFIC HYDROLYSIS OF A 2-ARYL-1,3-DIACYLOXY-2-PROPANOL; SYNTHETIC CHEMICAL INTERMEDIATES, FUNGICIDES | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-11-24 | — | — | US | disclosed |
| US-5654472-A | OPTICALLY PURE 2-ARYL-3-ACYLOXY-1,2-PROPANEDIOL COMPOUNDS; CHEMICAL INTERMEDIATES | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1997-08-05 | — | — | US | disclosed |
| EP-0704419-A1 | PROCESS FOR PRODUCING TRIAZOLE DERIVATIVE | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1996-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234441-A1 | NOVEL COMPOUNDS | LTB4R2, TSLP, LTB4R | CES2 3197/4885PLA2G4B 322/4885TSHR 3540/4885 |
| US-20120277279-A1 | Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions | NR3C1, SERPINA6, PTGS1 | CES2 4557/4885PLA2G4B 280/4885TSHR 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.